FDA’s General Wellness Software: De-Risking Your Digital Health Investment

The line between a helpful health application and a regulated medical device is often perceived as blurry, yet for digital health developers and product managers, misunderstanding this distinction carries significant regulatory and commercial risk. The FDA’s General Wellness Policy for Low Risk Devices provides critical clarity, outlining specific exclusions that determine when consumer health software avoids the rigorous premarket review processes associated with Software as a Medical Device (SaMD). A close textual analysis of this guidance reveals the precise boundaries, enabling developers to strategically architect their offerings to remain outside the regulatory perimeter or, conversely, to prepare for SaMD classification.

Defining Low-Risk General Wellness Software

The FDA’s guidance, reissued in 2026, carefully defines what constitutes a “general wellness product.” Such products must meet two primary criteria:

1. They are intended only for general wellness use, as described below.
2. They present a low risk to the safety of users and other persons.

The “general wellness use” criterion is further broken down into two categories. The first involves products that “promote a healthy lifestyle.” This includes technologies that:

• Are intended for weight management, physical fitness, relaxation, or stress management.
• Are intended to promote a healthy diet or healthy sleep.
• Are intended to promote mental acuity.
• Are intended to improve sexual function.

Importantly, these applications must not make any claims related to specific diseases or conditions. For instance, an application that tracks daily steps and calories burned, like many features found in Apple Inc.’s Health app or Fitbit devices, falls squarely within this category. These tools aid users in maintaining physical fitness without claiming to diagnose, treat, or prevent obesity or cardiovascular disease. The second category of general wellness use applies to products that “help consumers understand or maintain a healthy state, or reduce the risk of chronic diseases or conditions.” The key distinction here is that these products must only make claims that:

• Relate to a healthy lifestyle and are not intended to diagnose, cure, mitigate, treat, or prevent a disease or condition.
• Are well understood and accepted by the general public as promoting a healthy lifestyle.

An example might be a meditation app that claims to reduce stress, a generally accepted benefit of meditation, rather than claiming to treat anxiety disorder. The Consumer Technology Association has long advocated for clear distinctions, emphasizing the importance of fostering innovation in the wellness space without undue regulatory burden Consumer Technology Association position on health tech regulation.

The Critical Distinction: General Tracking vs. Clinical Diagnosis

The “low risk” criterion is paramount. The FDA clarifies that a general wellness product must not be invasive, involve implantation, or pose risks through technology like radiation. For software, the risk primarily revolves around the potential for inaccurate information to lead to harm. This is where the distinction between general health tracking and disease diagnosis becomes stark. Consider the difference:

“A mobile app that tracks calorie intake and provides general dietary advice to help users manage weight is considered a general wellness product. However, an app that analyzes dietary intake to diagnose or treat an eating disorder would be a medical device.” FDA guidance on mobile medical applications

Similarly, a Fitbit device that monitors heart rate for general fitness tracking purposes is a general wellness product. It helps users understand their physiological response to exercise. However, an AI-powered application that analyzes heart rate variability to detect early signs of atrial fibrillation, and then provides a clinical interpretation or recommendation for medical intervention, crosses the line into a SaMD. The latter is intended for a medical purpose (diagnosis or risk assessment of a disease) and thus requires FDA review. The absence of a defined SaMD pathway for companies operating in this ambiguous zone increasingly exposes them to enforcement actions. Regulated AI Health has observed a growing trend where health plans are scrutinizing digital health solutions more rigorously, often excluding those without clear regulatory standing from reimbursement or preferred vendor lists. This is a direct consequence of the FDA’s increasing clarity and willingness to enforce boundaries, alongside payers’ need for validated, safe, and effective tools.

Architecting for Non-Regulated Status: Apple and Fitbit as Exemplars

Apple Inc. and Fitbit (now part of Google) have largely navigated this field adeptly, with many of their core offerings remaining outside SaMD classification. Their success lies in carefully defining the intended use of their features. For instance, the Apple Watch’s activity tracking, sleep monitoring, and general heart rate monitoring features are presented as tools for a healthy lifestyle. They provide data and insights for users to understand their bodies better, but they stop short of offering medical diagnoses. When these companies do venture into medical device territory, they engage with the FDA. The Apple Watch’s ECG app and irregular rhythm notification feature, for example, underwent FDA clearance as SaMDs in late 2018. More recently, the Apple Watch’s AFib feature received FDA approval as a qualified tool in the Medical Device Development Tools (MDDT) program in May 2024, and a Hypertension Notification Feature received 510(k) clearance in September 2025. This demonstrates a clear understanding of the regulatory boundary: when the intended use shifts from general wellness to detecting a specific medical condition (atrial fibrillation or hypertension), the regulatory pathway changes accordingly. This SaMD-informed architecture, where medical features are distinct and appropriately cleared, allows them to offer a broad range of products while managing regulatory risk effectively. Similarly, Fitbit’s historical approach has been to focus on activity and sleep tracking for general wellness. While they collect vast amounts of physiological data, their primary consumer-facing claims generally align with promoting a healthy lifestyle. This strategic positioning has allowed them to scale their consumer offerings without the immediate burden of SaMD regulation for their core products.

Clear Criteria for Maintaining Non-Regulated Status

For digital health developers and product managers, the FDA’s General Wellness Guidance offers a roadmap. To maintain non-regulated status, software must:

1. Avoid Disease Claims: Do not state or imply that the product diagnoses, treats, cures, prevents, or mitigates any disease or medical condition. This includes using terms that suggest clinical efficacy for specific ailments.
2. Focus on General Wellness: Intended uses must align with promoting a healthy lifestyle, such as improving fitness, managing weight, promoting relaxation, or encouraging healthy habits.
3. Present Low Risk: The software should not pose a significant safety risk to the user. This means avoiding features that could lead to incorrect medical decisions if the information is flawed, or that involve invasive procedures or harmful energy.
4. Rely on Publicly Accepted Principles: If the product makes claims about health benefits, those benefits should be widely accepted as promoting a healthy lifestyle, not novel medical interventions.

Any deviation from these criteria, particularly the introduction of diagnostic or treatment claims, or the generation of information that directly informs clinical decision-making for a disease, will likely trigger SaMD classification. This transition means engaging with the FDA for premarket review, implementing a strong Quality Management System (QMS) compliant with ISO 13485, and developing clinical evidence to support safety and effectiveness. The absence of such a defined pathway, as exemplified by companies that operate in the gray area, not only invites FDA scrutiny but also jeopardizes commercial viability. Health plans and providers are increasingly wary of integrating solutions that lack regulatory clarity, seeing them as potential liabilities. The proactive approach taken by companies like Apple and Fitbit, segmenting their offerings and pursuing SaMD clearance where necessary, is a benchmark for sustainable growth in the digital health ecosystem. This analysis is sourced directly from the FDA’s General Wellness Policy for Low Risk Devices guidance document (reissued 2026) and related FDA publications.